Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL58805 in advanced tumors
NCT07179081Phase 1Recruiting
- Sponsor
- Advenchen Laboratories
- Start
- Dec 2020
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AL58805 in solid tumor (advanced stage) and lymphoma, sponsored by Advenchen Laboratories. Primary endpoint: Dose-limiting toxicity at 28 days. Started Dec 2020; status: recruiting.
02
Drugs
AL58805
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT07179081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07179081.